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Abstract
Ever since their discovery as cellular counterparts of viral oncogenes more than 25 years ago, much progress has been made in understanding the 
complex networks of signal transduction pathways activated by oncogenic Ras mutations in human cancers. The activity of Ras is regulated by 
nucleotide exchange factors (GEFs) and GTPase activating proteins (GAPs), and much emphasis has been put into the biochemical and structural 
analysis of the Ras/GAP complex. The mechanisms by which GAPs catalyze Ras-GTP hydrolysis have been clarified and revealed that oncogenic 
Ras mutations confer resistance to GAPs and remain constitutively active. However, it is yet unclear how cells coordinate the large and divergent 
GAP protein family to promote Ras inactivation and ensure a certain biological response. Different domain arrangements in GAPs to create differential 
protein-protein and protein-lipid interactions are probably key factors determining the inactivation of the 3 Ras isoforms H-, K-, and N-Ras and their 
effector pathways. In recent years, in vitro as well as cell- and animal-based studies examining GAP activity, localization, interaction partners, and 
expression profiles have provided further insights into Ras inactivation and revealed characteristics of several GAPs to exert specific and distinct 
functions. This review aims to summarize knowledge on the cell biology of RasGAP proteins that potentially contributes to differential regulation of 
spatiotemporal Ras signaling.
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Introduction
Over the last 2 decades, substantial prog-
ress in the understanding of signal trans-
duction at the molecular level has resulted 
in the identification of signaling cascades 
that are involved in the development of 
cancer. In particular, the complex net-
work of signaling pathways initiated by 
activated cell surface receptors to control 
a wide variety of cellular processes, 
including proliferation, differentiation, 
and apoptosis, has received strong inter-
est. H-, K-, and N-Ras were one of the 
first cellular proteins identified that link 
activated growth factor receptors with 
effector pathways that regulate cell 
growth and differentiation. Originally 
discovered as cellular counterparts of 
viral oncogenes, it soon became evident 
that mutations in codon 12, 13, and 61 
result in constitutively active Ras that 
is resistant to downregulation.1,2 Approx-
imately 20% to 30% of human tumors 
express oncogenic Ras, with mutations 
being most common in adenocarcinomas 
of the pancreas (90%), colon (50%), lung 
(30%), thyroid tumors (50%), and 
myeloid leukemia (30%).2,3 K-Ras muta-
tions are most frequent (85%) and 
predominantly found in pancreatic, 
colon, and lung cancers. N-Ras (15%) 
and H-Ras (<1%) mutations are less 
common and mainly found in myeloid 
leukemia and kidney and bladder can-
cers, respectively. In addition, aberrant 
activation of wild-type Ras (hyperactive 
Ras) can occur through deregulation of 
growth factor receptors or, as outlined in 
more detail below, via inactivation of 
negative Ras regulators.3-5 In this review, 
we will discuss the current models and 
views on Ras inactivation and how 
this might link to oncogenic activity of 
Ras isoforms and spatiotemporal Ras 
signaling.
Ras Inactivation
Ras proteins are predominantly localized 
at the inner leaflet of the plasma mem-
brane and act as binary switches, cycling 
between an inactive Ras-GDP and an 
active Ras-GTP. GTP-bound Ras is able 
to bind and activate effector pathways, 
including the Raf/mitogen-activated 
protein kinase (MAPK) and phosphati-
dylinositol-3-kinase (PI3K)/Akt signal-
ing cascades, which play central roles in 
cell growth and differentiation.3-6 The 
activity of the 3 Ras isoforms is con-
trolled by the ratio of bound GTP to GDP, 
and because Ras proteins have a very 
slow rate of GTP/GDP exchange and 
possess a very low intrinsic GTPase 
activity, these processes are regulated by 
GEFs and GAPs.7,8 GEFs enhance the 
rate of GDP dissociation, whereas GAPs 
accelerate the intrinsic Ras-GTPase 
activity to promote Ras inactivation by 
several orders of magnitude. Biochemi-
cal and structural analyses of the purified 
Ras/GAP complex identified glutamine 
61 of Ras and an arginine (arginine fin-
ger) provided by GAP as crucial to coor-
dinate Ras-GTP hydrolysis.9-11 Using the 
crystal structure of Ras complexed with a 
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nonhydrolyzable GTP analog, the molec-
ular mechanisms involved in GAP- 
mediated Ras-GTP hydrolysis were 
clarified, and we refer the reader to more 
detailed reports from others.7-11 In brief, 
phosphoryl transfer by GAPs requires the 
proper orientation of a water molecule 
attacking the γ-phosphate opposite to the 
GDP and stabilization of the transition 
state.7,8 The common oncogenic Ras 
mutation at glutamine 61 abolishes GAP-
induced hydrolysis, and mutations at 
positions 12 and 13 sterically block the 
proper orientation of glutamine 61 and 
the arginine finger, which is essential to 
stabilize the transition state.9-11 Interest-
ingly, several members of the GAP1 fam-
ily of RasGAPs display dual specificity 
to stimulate GTP hydrolysis of Ras as 
well as Rap1.8,12-15 While the requirement 
for dual GTPase activity of GAPs awaits 
further confirmation in physiological set-
tings, one can envisage that GAPs simul-
taneously regulating Ras and other small 
GTPases could integrate multiple signal 
transduction pathways.
Functional Differences  
of Ras Isoforms and  
Differential GAP Activity
H-, K-, and N-Ras are ubiquitously 
expressed and highly homologous, 
which was initially interpreted as an 
indication for redundancy within the 
Ras family. Yet, the association of differ-
ent mutation rates of Ras isoforms in 
different cancers already gave funda-
mental clues of functional differences.1-3 
In addition, knockout mice revealed 
essential roles for K-Ras in develop-
ment, while H- and N-Ras appeared dis-
pensible for mouse embryogenesis.16-19 
Along these lines, defects in human 
development have recently been associ-
ated with Ras isoform–specific func-
tions.19-21 The different magnitude of 
oncogenic Ras isoform signaling further 
supports signal specificity of Ras iso-
forms. Although there is some contro-
versy about the differential ability of 
Ras isoforms to activate downstream 
effectors, some studies suggested that 
H-Ras strongly activates the PI3K/Akt 
pathway, while K-Ras is a more potent 
activator of the Raf/MAPK pathway. 
Different potencies of Ras isoforms to 
induce cellular transformation and dif-
ferential Ras isoform gene expression 
patterns seem to further contribute 
to establish differential Ras isoform 
signaling.22,23
Altogether, these findings implicate 
that Ras activation and inactivation must 
be fine tuned and tightly regulated. 
But how do cells coordinate the GAP pro-
tein family in space and time to mediate a 
certain biological response? Different 
domain arrangements in GAPs to create 
differential protein-protein and protein-
lipid interactions are probably key factors 
determining the GTP/GDP ratio bound 
to H−, K−, and N-Ras.14,24-30 Cell- and 
animal-based studies examining GAP 
activity, interaction partners, and expres-
sion profiles have provided further 
insights into Ras inactivation in normal 
and transformed cells. Mammalian pro-
teins capable of functioning as GAPs for 
H-, K-, and N-Ras represent a large and 
divergent protein family and include 
p120GAP, neurofibromin (NF1), the 
GAP1 family, including GAP1IP4BP, Ca2+-
promoted Ras inactivator (CAPRI), Ras 
GTPase activating-like protein RASAL, 
as well as the SynGAP family (DAB2IP, 
nGAP, SynGAP).14,24-30 Some of those 
are expressed ubiquitously, while others 
show very restricted expression profiles, 
making it difficult to assign a member 
of the GAP family with Ras inactivation 
in a given cell/tissue. In addition, struc-
tural analysis indicated that NF1 and 
p120GAP bind Ras isoforms without any 
preference.9-11
Yet, an increasing number of studies 
suggest that differential GAP expression 
patterns and Ras/GAP assembly must be 
involved in cellular transformation. NF1, 
which is a tumor suppressor only in neu-
ronal and myeloid cells,25-28 is probably 
the best example for the tissue-specific 
transforming potential of an individual 
member of the GAP protein family. 
CAPRI confers tumor suppressor activity 
in mammary epithelial cells,31 and RASAL 
is downregulated in tumors from the 
brain, skin, bladder, head, and neck as 
well as multiple cell lines from the naso-
pharynx, breast, lung, liver, and esopha-
gus.32 Recently, loss of RASAL activity 
was correlated with hyperactive Ras in 
the colon and hepatocellular carcinoma 
lacking oncogenic Ras.33,34 In some can-
cers, diminution of RASAL is probably 
due to the downregulation of the tran-
scription factor PITX1, which is required 
for RASAL mRNA expression.35 Fur-
thermore, expression of DAB2IP, a less 
well-characterized member of the Syn-
GAP family, is often silenced in hepato-
cellular carcinoma.36
While earlier studies were not able to 
link p120GAP with tumor suppressor 
activity in human cancers, more recent 
work has associated p120GAP mutations 
with malfunctions in angiogenesis.37 
Moreover, we recently demonstrated 
that p120GAP-mediated inactivation 
of epidermal growth factor receptor 
(EGFR)–induced Ras/MAPK signaling is 
facilitated by annexin A6 (AnxA6), a 
member of the annexin protein family.30,38 
Loss of AnxA6 in EGFR-overexpressing 
and estrogen receptor (ER)–negative 
breast cancer cells (BCCs) is associated 
with elevated Ras, Raf, and MAPK activ-
ity, and vice versa, upregulation of AnxA6 
strongly reduces cell growth of EGFR-
overexpressing BCCs.39,40
Taken together, the potential tumor-
suppressive function of each GAP is 
associated with elevated Ras activity but 
seems to be restricted to certain cell 
types, and it is tempting to speculate that 
specific GAPs control Ras activity in 
different tissues, but their inhibition is a 
general mechanism to provoke onco-
genic activity and carcinogenesis via 
elevated wild-type Ras activity. In sup-
port of this hypothesis, the different 
domain arrangements in GAPs point at 
different functions and interactions.24-30
Subcellular Localization  
of Ras Signaling Complexes
In addition to complex expression pro-
files and different interaction partners 
determining the ability of the various 
GAP proteins to associate with H-, K-, 
or N-Ras, it has become evident that the 
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subcellular localization of Ras isoforms 
is another major determinant of signal 
output and biological response. This 
includes the different localization and lat-
eral segregation of activated Ras iso-
forms in different microdomains of 
the plasma membrane but also Ras 
isoform–specific signaling from different 
endomembranes.19,41-43 The stabilization 
of microdomains containing different 
Ras isoforms could then provide plat-
forms for the differential recruitment 
of GAPs and other Ras regulators/ 
effectors, leading to the formation of 
signal- and compartment-specific protein 
complexes.19,41-43
It would go beyond the scope of this 
review to summarize the literature on the 
microlocalization of Ras isoforms, and 
we refer the reader to more detailed 
reviews from others on this topic.19,41-43 
Most of the current knowledge on Ras 
isoform localization is based on ectopic 
expression of tagged Ras isoforms, either 
utilizing fluorescent proteins or short 
sequence motifs to target Ras isoforms to 
specific localizations at the cell surface or 
to endomembranes. Limited sensitivity 
of currently available technology is still 
impeding verification of the majority of 
these findings for endogenous H-, K-, 
and N-Ras. In summary, based on the Ras 
isoform overexpression studies, at the 
plasma membrane, H- and K-Ras are 
believed to be localized in largely non-
overlapping microdomains (nanoclus-
ters), and their distributions are modulated 
by GTP/GDP exchange, thus GEF and 
GAP activity. H-Ras-GDP is predomi-
nantly found in cholesterol-sensitive 
domains (lipid rafts/caveolae), whereas 
active H-Ras preferentially targets 
cholesterol-independent microdomains. 
Both active and inactive K-Ras is local-
ized in cholesterol-independent nanoclu-
sters, which are physically distinct from H- 
Ras-GTP–containing microdomains. N- 
Ras-GTP is mainly found in cholesterol- 
sensitive membrane domains. It was 
initially believed that Ras signaling 
occurs exclusively at the plasma mem-
brane, but since the discovery of active 
Ras in the endoplasmic reticulum and 
Golgi complex,43,44 all 3 Ras isoforms 
have been detected in endosomes45-47 and 
mitochondria.48-50 Thus, Ras isoforms 
cannot be considered stationary but trans-
locate between cellular compartments. 
The presence of Ras in multiple cellular 
locations must have consequences for the 
regulation of Ras activation and inactiva-
tion. Indeed, several studies implicate 
differential participation of certain GEFs 
to promote Ras activation at the 
endoplasmic reticulum or the Golgi 
complex.51-53
Despite the increased knowledge on 
the mechanisms that target active H-, K-, 
and N-Ras into different microdomains at 
the plasma membrane and intracellular 
localizations, the recruitment of GAPs to 
specific Ras-containing microdomains is 
still poorly understood. Current models 
suggest that active Ras recruits regulators 
and effectors in small (<15 nm) signaling 
platforms.19,41-43 Electron microscopy 
and single-particle tracking studies 
showed activated H- and K-Ras to 
become transiently immobile, possibly to 
recruit downstream effectors, such as Raf 
and MAPK.41-43 Similarly, once the Ras 
binding domain of p120GAP is recruited 
to the membrane, it is transiently immo-
bile to interact with H- and K-Ras-GTP.54 
Given that some full-length GAPs act 
differently compared to their GAP 
domains,15 it is still to be determined if 
this mechanism also applies for full-
length p120GAP or other GAPs.
The different localization of Ras iso-
forms is likely to create a microenviron-
ment that enables differential recruitment 
of GAPs for Ras inactivation. As 
described in more detail below, the vari-
ous protein domains and second messen-
gers promoting membrane association 
of NF1, p120GAP, CAPRI, RASAL, 
GAP1m, GAP1IP4BP, and SynGAP proba-
bly reflect the need and adaptation to 
ensure efficient targeting of all Ras iso-
forms in any cellular location. All GAPs 
are characterized by a multiple domain 
structure,24-30 and modules such as 
the src homology 2 (SH2), SH3, pleck-
strin homology (PH), Ca2+-dependent 
phospholipid-binding/conserved region 2 
(CALB/C2), and the Bruton tyrosine 
kinase Cys-rich (BTK) domain probably 
enable targeting of any Ras isoform by at 
least one GAP independent of Ras iso-
form microdomain localization. But little 
is yet known how protein-protein and 
protein-lipid interactions and calcium 
(Ca2+) coordinate the targeting of the GAP 
family members to different Ras isoforms 
in various locations in different cells and 
tissues.
In addition, targeting/scaffolding 
proteins are likely to stabilize Ras/ 
GAP assembly directly/indirectly via 
interacting with GAPs and/or Ras or via 
membrane microdomain formation/ 
stabilization. Several scaffolds for Ras 
isoforms and Raf and MAPK kinases 
have been identified, which is reviewed in 
detail elsewhere.4,19,41,42,55,56 Scaffolds sta-
bilizing protein-protein and protein-lipid 
interactions of GAPs via their SH2, SH3, 
PH, C2, and even GAP domains probably 
contribute to determine membrane target-
ing and Ras/GAP assembly in certain cel-
lular locations. This includes proteins like 
14-3-3, AnxA6, receptor for activated C 
kinase 1 (RACK1), syndecan 2 for 
p120GAP, and NF1, respectively. In addi-
tion, the differential interaction of GAPs 
with growth factor receptors, protein 
kinase C (PKC), but also regulators of 
actin remodeling, such as RhoGAPs and 
Rac/Rho GTPases, and other yet unknown 
proteins provides further opportunity for 
signal complex specificity.14,24-30
To date, experimental evidence for 
GAP activity is almost exclusively asso-
ciated with Ras inactivation at the plasma 
membrane. NF1 has been found at the 
plasma membrane and multiple intra-
cellular localizations and could thus be 
involved in Ras inactivation in various 
endomembranes.57-59 The fact that 
p120GAP remains associated with EGFR 
in endosomes60 is another indication for 
the involvement of GAPs in the regula-
tion of spatiotemporal Ras signaling, as 
active H-Ras is internalized with EGFR 
after stimulation.45 The targeting protein 
for p120GAP, AnxA6, is also found in 
endosomes and able to bind active 
H-Ras.30,39,40 Altogether, this could 
ensure H-Ras signal termination both at 
the plasma membrane and in early endo-
somes upon EGFR activation.
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Only few studies investigated the 
association of GAPs with cholesterol-
rich membrane microdomains (lipid 
rafts), which are important for H- and 
N-Ras signaling.19,41 For instance, NF1 
binds to the scaffolding domain of cave-
olin, the major structural protein found 
in caveolae, a subtype of lipid rafts.61 
NF1 contains 4 potential caveolin- 
binding domains, and interestingly, mis-
sense mutations in NF1 patients occur 
with high frequency in 3 of the 4 putative 
caveolin-binding domains.61 Similarly, 
SynGAP was found in lipid rafts from 
neuronal cells.62 p120GAP complexed 
with scaffold proteins such as synde-
can-2, RACK1, and AnxA6 probably 
fine tunes the association with rafts and 
nonrafts.30,40,63-65 Future studies will have 
to clarify if GAP localizations associated 
with lipid rafts can be linked to H- and 
N-Ras inactivation at the cell surface.
Membrane Targeting and 
Regulation of GAP Activity
GAP-mediated inactivation of Ras 
requires the translocation of GAPs to the 
plasma membrane followed by Ras/GAP 
complex formation and stimulation of 
Ras-GTPase activity. The coordinated 
recruitment of the various GAPs to H-, 
K-, and N-Ras in a given cell is still 
unclear. Yet, the dynamics of targeted 
membrane association and release into the 
cytosol upon Ras inactivation provides an 
opportunity to reversibly target specific 
GAP proteins to different Ras isoforms in 
various locations within the cells. In the 
following, we will not aim to give a 
detailed review of each GAP, as several 
comprehensive reviews covering NF1, 
p120GAP, and the GAP1 family have 
been published recently.14,24-30 The aim of 
this section is to highlight aspects that 
could contribute to differential GAP mem-
brane targeting and Ras/GAP assembly.
NF1
Loss of neurofibromin (NF1) is to date the 
only mutation for Ras-specific GAPs 
known to cause tumor predisposition disor-
ders in humans.26-28 NF1 encodes a 320-kD 
protein, and clinical manifestations of NF1 
include multiple benign and malignant 
neurofibromas as well as gliomas, pheo-
chromocytomas, and myeloid leukemias. 
NF1 is ubiquitously expressed but most 
abundant in neurons, Schwann cells, astro-
cytes, oligodendrocytes, and leuko-
cytes.26-28 The tumor suppressor activity of 
NF1 is believed to occur through its Ras-
GAP domain, as loss of NF1 results in 
hyperactive Ras and increased activity of 
downstream effectors such as the Raf/
MAPK and PI3K/Akt pathway.27,66
While NF1 reduces overall Ras activity 
and appears to interact with all 3 Ras iso-
forms,9-11 the ability of NF1 to downregu-
late each Ras isoform in cells and 
tissues is not fully characterized. Neuro-
logical deficits in NF1 knockout mice can 
be rescued by K-Ras depletion and pharma-
cological inhibition of Ras using farnesyl 
transferase inhibitors (FTIs) or lovastatin, 
which interferes with Ras prenylation, sug-
gesting that NF1 can target all Ras iso-
forms.27 NF1 appears to be localized in 
multiple cellular locations,57-59 but rela-
tively little is known how NF1 localization 
and activity are regulated. Besides the cen-
tral RasGAP domain, the remaining 
sequence contains an N-terminal cystein/
proline-rich domain (CSRD) and a C-ter-
minal domain (CTD) with a nuclear local-
ization signal57,67 but lacks the domains 
common to the other GAPs. Relevant for 
NF1 membrane targeting is most likely a 
bipartite phospholipid-binding Sec14-PH 
module adjacent to the RasGAP domain.68 
The biological role of the Sec14 domain is 
still unclear, but its yeast homolog Sec14p 
is implicated in protein and lipid traffick-
ing,69 and Sec14-like domains have been 
found in a number of mammalian lipid-
binding proteins.70 In recent follow-up 
studies, several glycerophospholipids, in 
particular phosphatidylethanolamine and 
phosphatidylglycerol, were found to inter-
act with the Sec14 domain.70 Thus, the 
Sec14 module could facilitate NF1 interac-
tion with glycerophospholipids in certain 
compartments to selectively regulate dis-
tinct Ras signaling pathways.
Several other proteins are likely to impact 
on NF1 localization. Phosphorylation sites 
within the CT domain are constitutively 
phosphorylated by protein kinase A 
(PKA).71,72 The phosphorylation of these 
serine and threonine residues is important 
for interaction of NF1 with 14-3-3 pro-
teins, which negatively regulates the Ras-
GAP activity of NF1.72 In addition, 
protein kinase C (PKC) has also been 
shown to phosphorylate NF1.73,74 In 
response to EGF, PKCα-mediated phos-
phorylation of NF1 increases its RasGAP 
activity and also its interaction with 
actin.73 Altogether, this might point at 
NF1 targeting K-Ras at the plasma mem-
brane, which requires an intact actin cyto-
skeleton for signaling.75 Further implicating 
protein kinases in NF1 localization and 
activity, NF1 can be degraded via the pro-
teosome with growth factors that stimulate 
both G protein–coupled receptors and 
receptor tyrosine kinases.76 Recently, Phan 
et al. identified the ETEA/UBXD8 protein 
to interact and promote NF1 ubiquitination 
and degradation, which would ultimately 
regulate the amount of NF1 at the cell sur-
face.77 It is unknown if these findings are 
linked to earlier studies reporting that NF1 
phosphorylation inhibits its lysosomal deg-
radation.78 Interestingly, ETEA/UBXD8 
does not interact with p120GAP,77 the other 
ubiquitously expressed RasGAP, indicative 
of this interaction contributing to differen-
tial and spatiotemporal Ras signaling.
In this context, it should be noted that 
the localization of protein kinases such 
as PKC and PKA is regulated by scaf-
fold proteins, including RACKs, A 
kinase anchoring proteins (AKAPs), and 
annexins,79-83 all of which facilitate the 
complex and spatiotemporal targeting of 
PKC and PKA to unique subcellular 
localization to be part of specialized sig-
naling complexes. The complex inter-
play of protein kinases with their specific 
scaffolds could therefore determine NF1 
and, as outlined below, p120GAP activ-
ity and localization.
p120GAP
The modular structure of p120GAP is 
probably the basis for its multiple inter-
action partners and functions that go 
beyond Ras inactivation, which has been 
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summarized in detail.26,29,30,37 p120GAP 
is ubiquitously expressed and has been 
implicated in the downregulation of 
EGF, platelet-derived growth factor 
(PDGF), insulin, colony-stimulating 
factor, and ephrin receptors. In addition, 
the N-terminal region of p120GAP 
exerts effector functions that appear 
independent of its GAP activity.26,29 
Here, we want to focus on mechanisms 
that are involved in Ras/GAP assembly 
and Ras inactivation. The modular struc-
ture of p120GAP includes an SH3 
domain flanked by 2 SH2 domains, fol-
lowed by a PH, CALB/C2, and the GAP 
domain. The coordinated interaction of 
these domains with other proteins, 
including protein kinases, adaptors, and 
scaffolding proteins, probably organizes 
p120GAP membrane recruitment and 
Ras/GAP assembly.
SH2 domains facilitate the binding of 
p120GAP to activated EGF, PDGF, and 
other receptor tyrosine kinases, such as 
insulin receptors.29,30,84-86 Several nonre-
ceptor tyrosine kinases, including Src, 
also interact with the SH2 domains of 
p120GAP.87,88 Dok-1 (p62dok) is an adap-
tor that binds to the p120GAP SH2 
domain89 and was initially identified as a 
tyrosine-phosphorylated, 62-kDa pro-
tein associated with p120GAP in chronic 
myelogenous leukemia (CML) and in 
v-Abl–transformed B cells.90,91 It later 
turned out to be the prototype of the Dok 
adaptor protein family, which plays key 
roles in the inhibition of cell prolifera-
tion and Ras/MAPK signaling triggered 
by diverse stimuli through receptor and 
nonreceptor kinases.89
As mentioned above, mutational 
defects in p120GAP cause abnormal 
angiogenic remodeling in capillary 
malformation–arteriovenous malforma-
tion (CM-AVM) that cannot be compen-
sated by other RasGAPs.37 These 
observations underscore a prominent 
and specific role for p120GAP in Ras 
signaling pathways regulating the actin 
cytoskeleton. In support of this, multiple 
binding partners of p120GAP as well as 
results from the p120GAP knockout 
mice provide links to actin remodeling. 
For instance, the SH2 domains bind 
p190-RhoGAP and focal adhesion 
kinase (FAK), which both regulate the 
GTPase activity of Rho GTPases.92-94 
Furthermore, the SH3 domain in 
p120GAP, which is unusual because of 
its inability to interact with proline-rich 
motifs, binds the calpain subunit Capns1 
and has been implicated in Rho-medi-
ated cytoskeletal rearrangements.95,96 
Altogether, this could indicate that SH2 
and SH3 domains recruiting p120GAP 
to specific plasma membrane microdo-
mains involved in actin remodeling, 
where coordination of Ras and Rho reg-
ulated signaling pathways, for example, 
for the formation of stress fibers, focal 
adhesions, establishment of cell polarity, 
and cell migration, are essential.92-96
Little is known about the PH domain 
in p120GAP, which generally facilitates 
binding to phosphoinositides in mem-
branes or in some cases proteins.97 Some 
evidence suggests that the PH domain 
can interfere with Ras/GAP assembly.98 
In addition, interaction of RACK1 with 
the PH domain of p120GAP has been 
described.64,65 RACK1 is a scaffold for 
PKCα, which in earlier studies was 
shown to regulate p120GAP activity in 
T lymphocytes,99 but also might target 
p120GAP to cholesterol-rich membrane 
domains, such as caveolae, in other 
settings.100
By extending the previous work from 
Davis et al.,101 we demonstrated that 
AnxA6 binds to the CALB/C2 domain 
of p120GAP to facilitate the Ca2+-
dependent recruitment of p120GAP to 
inactivate H-Ras at the plasma membrane 
upon EGFR activation.30,39,40 For a more 
comprehensive description of the AnxA6/
p120GAP complex and its involvement 
in Ras inactivation upon EGFR activa-
tion, we refer the reader to previous 
reviews from our laboratories.30,40,102 As 
mentioned above, AnxA6/p120GAP 
inhibiting H-Ras might also be opera-
tional in early endosomes.30,40-45,60,102 
Reduced growth of EGFR-overexpress-
ing A431 cells ectopically expressing 
AnxA6 in mouse xenografts supports 
tumor suppressor activity of the AnxA6/
p120GAP complex.103 Further emphasiz-
ing AnxA6 to create signal specificity, 
overexpression of p120GAP, but not 
CAPRI, inhibits Ras/MAPK activity in 
AnxA6-expressing BCCs.39 It remains to 
be determined if AnxA6-mediated inhibi-
tion of H-Ras via membrane recruitment 
of p120GAP is linked to earlier reports 
identifying several fatty acids, including 
arachidonic acid, and their metabolites, 
eicosanoids, as potent inhibitors of 
p120GAP and NF1.104,105 Recent studies 
from our laboratory revealed decreased 
cytoplasmic phospholipase A
2
 (cPLA
2
) 
activity in cells expressing elevated lev-
els of AnxA6,106 and it is tempting to 
speculate that the reduced ability of 
cPLA
2
 to cleave arachidonic acid from 
phospholipids in certain membrane 
microdomains creates a microenviron-
ment that potentiates and stabilizes 
p120GAP membrane association and 
H-Ras/p120GAP assembly.
We have also demonstrated that 
AnxA6 stimulates the Ca2+-inducible 
involvement of PKCα in the regulation of 
H-Ras and possibly EGFR signal trans-
duction pathways.40,102,107 On the other 
hand, Agell et al. identified PKC-
mediated and calmodulin (CaM)–depen-
dent phosphorylation of K-Ras to 
modulate K-Ras activity and func-
tion.108,109 In these studies, it was pro-
posed that microdomains of nonphos- 
phorylated K-Ras would be more 
accessible to p120GAP, consequently fol-
lowed by K-Ras inactivation, whereas 
segregation of phosphorylated K-Ras 
into other microdomains would recruit a 
different set of effectors. Hence, interplay 
of RACK1, AnxA6, and CaM might 
coordinate the involvement of PKCα in 
the regulation of p120GAP localization 
and activity for H- and K-Ras.
Together with the ability of AnxA6 to 
modulate caveolae formation and induce 
actin rearrangements at the plasma 
membrane,110-112 it is evident that the 
multiple features that determine AnxA6 
localization and protein-protein interac-
tion, together with the SH2, SH3, and 
PH domains within p120GAP, create a 
unique combination of targeting signals
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to direct p120GAP into specific micro-
domains in multiple locations.
The GAP1 Family
The mammalian GAP1 family consists 
of GAP1m, GAP1IP4BP, CAPRI, and 
RASAL, and their role in the regulation 
of Ras inactivation has been reviewed in 
detail by Cullen and coworkers.14,24 In 
this section, we will briefly summarize 
previous findings and highlight recent 
data that suggest the dual Ras and 
Rap1 GAP activity of the GAP1 family 
contributing to spatiotemporal Ras 
signaling.
GAP1m and GAP1IB4BP
The GAP1 family is characterized by a 
conserved domain structure with 2 
N-terminal C2 domains, followed by the 
central GAP domain and C-terminal PH 
domain that contains a BTK motif. 
Membrane recruitment of GAP1m and 
GAP1IB4BP is facilitated by their PH 
domains, which are well established to 
act as binding sites for phosphoinositi-
des and proteins but are generally 
believed to confer little specificity and 
low affinity.97 However, the PH domains 
of GAP1m and GAP1IB4BP bind phospha-
tidylinositol 3,4,5-triphosphate (PIP
3
) 
with high affinity, and GAP1IB4BP also 
displays affinity for phosphatidylinosi-
tol 4,5-bisphosphate (PIP
2
).113 Sequence 
variations in their PH domains seem to 
allow selective interaction with particu-
lar phosphoinositide head groups.113-116 
Cytosolic GAP1m undergoes rapid mem-
brane translocation upon elevation in 
plasma membrane PIP
3
 levels because 
of activation of cell surface receptors 
that couple to class I PI3K. Given the 
potential role of PI3K in signaling events 
in lipid rafts, these mechanisms could be 
involved in N-Ras inactivation and/or 
the lateral movement of active H-Ras 
out of lipid rafts.
In contrast to GAP1m, GAP1IB4BP is 
constitutively localized at the plasma 
membrane probably because of the high 
levels of PIP
2
 that are constantly found 
at the inner leaflet of the plasma mem-
brane. Little is known about the 
regulation of the RasGTPase activity of 
GAP1IB4BP. Recently, one study identi-
fied the involvement of GAP1IB4BP in the 
dopamine D2 receptor–mediated inhibi-
tory regulation of endocrine functions in 
pituitary cells via the Ras/MAPK 
pathway.117
However, the ability of GAP1IB4BP to 
function as a Rap1 GTPase-activating 
protein indicates that depending on the 
cellular microenvironment, GAP1 GAPs 
might target Rap1 as well as Ras 
GTPases.12-15 Indeed, all GAP1 family 
members except GAP1m and even Syn-
GAP can stimulate Rap1-GTP hydroly-
sis.12-15,118 At first, these unexpected 
findings appeared difficult to interprete, 
as GAPs specific for Ras and Rap1 act 
differently. Unlike Ras, Rap1 does not 
possess a glutamine at position 61, and 
RapGAPs do not employ a catalytic argi-
nine residue (arginine finger) but provide 
an asparagine (asparagine thumb) to 
stimulate GTP hydrolysis.12-15 Interest-
ingly, the RasGAP domain of GAP1IP4BP 
is sufficient to drive the hydrolysis of 
Rap1-GTP,13 and recent studies suggest 
that the GAP domain of GAP1IP4BP and 
RASAL can undergo conformational 
changes that enable them to interact with 
either Ras or Rap1.15 Hence, both Ras 
and Rap1 GTPases might compete for 
GAP1IP4BP and RASAL recruitment in 
cells, and the local concentration of Ras 
and Rap1 in any microenvironment might 
determine the biological activity of these 
GAPs.
CAPRI and RASAL
CAPRI and RASAL both contain a pair 
of CALB/C2 domains with a full set of 5 
Ca2+-coordinating acidic residues that, 
upon Ca2+ increase, mediate the rapid 
recruitment of cytosolic CAPRI and 
RASAL to the membrane to inhibit Ras 
and MAPK.14,119,120 Most strikingly, 
CAPRI and RASAL respond to distinct 
temporal aspects of the Ca2+ signal. 
Whereas CAPRI is constantly associated 
with the membrane in response to Ca2+, 
RASAL senses the frequency of Ca2+ 
oscillations by undergoing synchronous 
and repetitive oscillatory associations 
with the plasma membrane.121-123 Consis-
tent with CAPRI promoting Ras GTPase 
activity, Fcγ receptor (FcγR) activation in 
macrophages from CAPRI-deficient 
mice is associated with strong Erk activa-
tion.124 However, the impaired immune 
response after bacterial infection of these 
mice is probably due to the uncoupling of 
FcγR-mediated phagocytosis from Rac1 
and Cdc42 activation. Rac1 and Cdc42 
are both Ras-related GTPases that are 
necessary for actin reorganizations dur-
ing the formation of the phagocytic cup. 
Interestingly, CAPRI constitutively inter-
acts with both Rac and Cdc42 via its Ras-
GAP domain and appears to recruit both 
GTPases during FcγR-mediated phago-
cytosis.124 This scaffolding function of 
CAPRI might be similar to the one of 
IQGAP, which also stabilizes active Rac 
and Cdc42.125 The ability of CAPRI, and 
possibly RASAL, to act as a scaffold, 
together with their dual GAP specificity 
towards Ras and Rap1, is likely to com-
pete with their involvement in Ca2+-
mediated Ras inactivation.
Differential Expression  
of GAPs in Cancer
Several recent studies have analyzed the 
expression patterns of various RasGAPs 
in different cancers, altogether support-
ing a model of the GAP protein family 
differentially contributing to tumorigen-
esis in different organs. Two indepen-
dent RNA interference studies originally 
identified RASAL and CAPRI as poten-
tial tumor suppressors in cell culture 
models. While CAPRI reduced transfor-
mation in mammary epithelial cells,31 
Kolfschoten et al. used a transformation 
model that only requires Ras for trans-
formation and identified RASAL to pos-
sibly inhibit cell growth in prostate, 
bladder, and colon cancer. In these stud-
ies, downregulation of RASAL was 
achieved through transcriptional control 
driven by PITX1.35 These findings 
increased interest to examine the poten-
tial role of RASAL in oncogenesis, 
which is highly expressed in the thyroid 
and adrenal medulla but only found in 
residual amounts in the brain, spinal 
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cord, and trachea.126 Jin et al. provided 
strong evidence that expression of 
RASAL, but not CAPRI or PITX1, is 
silenced through CpG methylation in 
multiple tumors, including the brain, 
skin, bladder, head, and neck. Impor-
tantly, ectopic expression of RASAL 
suppressed the malignant phenotype of 
tumor cells with silenced RASAL.32
Until recently, a role for RasGAPs in 
colorectal cancers (CRC) was unknown, 
but recent studies identified RASAL as 
being significantly downregulated in all 
CRC lines that express wild-type K-Ras.34 
Knockdown and overexpression experi-
ments support a role of RASAL as a neg-
ative regulator of wild-type K-Ras in 
CRC cells. Primary CRC tumors revealed 
a correlation between RASAL levels and 
CRC disease progression, implicating a 
prognostic role for RASAL in colon 
cancer.34 Interestingly, reduced RASAL 
levels were predominantly observed in 
tumors of the distal colon and rectum, 
indicating that particular cells defined by 
their tissue location are particularly vul-
nerable to RASAL depletion. Similar to 
the studies described above, methylation 
of the RASAL gene in several CRC lines 
was observed, which further emphasizes 
epigenetic silencing of RASAL contrib-
uting to tumorigenesis.34
Aberrant activation of wild-type Ras 
and its downstream effector pathways is 
also common in human hepatocellular 
carcinomas (HCC). In a large collection 
of human HCC, Calvisi et al. identified 
that in HCC with hyperactive wild-type 
Ras, but lacking Ras mutations, either 
RASAL, DAB2IP, NF1, or the RASAL 
inducer PTX1 was downregulated.33 
Strikingly, all HCCs exhibited promoter 
methylation of RASAL, DAB2IBP, or 
NF1, indicating that silencing of GAP 
mRNA expression can contribute to 
oncogenic events leading to increased 
wild-type Ras activity in HCC. Interest-
ingly, elevated levels of several other 
GAPs did not appear to compensate for 
the loss of RASAL, DAB2IP, or NF1 
nor reduce elevated Ras activity and cell 
growth in these liver cancers.33 Further 
highlighting the involvement of RASAL 
in liver carcinogenesis, PITX1 is fre-
quently silenced by promoter hyper-
methylation.127 Low DAB2IP and PTX1 
levels in HCC subclasses characterized 
by poor survival could indicate an 
involvement in tumor aggressiveness.
Similarly, epigenetic silencing of 
DAB2IP in HCC has been reported by 
others.36 DAB2IP, which is a RasGAP 
associated with the disabled gene family 
member DAB2, is also silenced in pros-
tate, breast, lung, and gastrointestinal 
tumors through aberrant promoter 
CpG methylation.128-132 Furthermore, 2 
genome-wide studies identified DAB2IP 
as a putative tumor suppressor in aggres-
sive prostate adenocarcinoma.133 Unfor-
tunately, little is known about the 
regulation of DAB2IP in vivo and cor-
relation to Ras activity in the cancer 
samples analyzed, but together with the 
observations described below, epigene-
tic silencing of the various GAPs impli-
cates a general theme that requires 
further investigation.
It is evident that the concept of dif-
ferential expression patterns and epigen-
etic silencing conferring specificity for 
Ras/GAP assembly also extends to the 
various scaffolds and kinases targeting 
p120GAP. In this context, we just want 
to highlight AnxA6, the membrane- 
targeting protein for p120GAP. Although 
AnxA6 is often viewed as a ubiquitous 
and abundant protein, it is not expressed 
in epithelial cells of the small intestine, 
kidney (including the parathyroid gland), 
and colon, which have low to undetect-
able amounts of AnxA6.30,40 In several 
tumors and cancer models, loss of 
AnxA6 correlates with elevated Ras 
activity and tumor progression, which 
has been reviewed in detail.30,40,102 
Perhaps the best examples are EGFR-
overexpressing and ER-negative BCCs 
and A431 skin carcinoma cells with low 
or undetectable amounts of AnxA6, 
respectively, probably because of pro-
moter methylation.39,134 In addition, loss 
of large regions of chromosome 5q 
(5q31-q35), which carries the AnxA6 
locus, is associated with ER-negative 
tumors carrying ErbB2 gene amplifica-
tions as well as myelodysplastic syn-
drome and risk of transformation to acute 
myelogenous leukemia (AML).39,40,135 
Thus, AnxA6 might display tumor sup-
pressor activity only in the context of 
certain genetic lesions (e.g., EGFR lev-
els) or susceptible cell types.
Conclusion
Even though it has been known for almost 
2 decades that Ras mutations contribute 
to tumorigenesis in a large number of 
human cancers, the identification of strat-
egies to selectively inhibit oncogenic Ras 
has remained one of the major challenges 
in cancer therapeutics. In addition, in a 
large number of cancers, Ras signaling is 
often upregulated because of an increased 
coupling to overexpressed or deregulated 
growth factor receptors. As pointed out 
above, the differential and cell type–spe-
cific activity and expression patterns of 
GAPs will modulate the contribution of 
each GAP in Ras inactivation. In addi-
tion, a complex cellular machinery of 
scaffold and adaptor proteins facilitates 
the targeting, assembly, and stabilization 
of Ras/GAP complexes in specific sub-
cellular compartments. It is this cellular 
machinery that creates a cell-specific and 
locally restricted microenvironment to 
channel signaling information arriving 
from the extracellular milieu to the right 
location, thereby providing an efficient 
and accurate biological response. Map-
ping the association and composition of 
GAPs in Ras isoform–containing signal-
ing modules at the plasma membrane and 
endomembranes in space and time will 
not only provide a better understanding 
of spatiotemporal Ras signaling but also 
hopefully identify new targets and thera-
peutic approaches aiming to downregu-
late Ras-GTP levels in cancer.
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